Literature DB >> 32205655

Clinical Update on Checkpoint Inhibitor Therapy for Conjunctival and Eyelid Melanoma.

Jonathan E Lu, Jessica R Chang, Jesse L Berry, Gino K In, Sandy Zhang-Nunes.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32205655      PMCID： PMC8059069          DOI： 10.1097/IIO.0000000000000308

Source DB:  PubMed          Journal:  Int Ophthalmol Clin        ISSN： 0020-8167


× No keyword cloud information.
  72 in total

1.  Nivolumab in previously untreated melanoma without BRAF mutation.

Authors:  Caroline Robert; Georgina V Long; Benjamin Brady; Caroline Dutriaux; Michele Maio; Laurent Mortier; Jessica C Hassel; Piotr Rutkowski; Catriona McNeil; Ewa Kalinka-Warzocha; Kerry J Savage; Micaela M Hernberg; Celeste Lebbé; Julie Charles; Catalin Mihalcioiu; Vanna Chiarion-Sileni; Cornelia Mauch; Francesco Cognetti; Ana Arance; Henrik Schmidt; Dirk Schadendorf; Helen Gogas; Lotta Lundgren-Eriksson; Christine Horak; Brian Sharkey; Ian M Waxman; Victoria Atkinson; Paolo A Ascierto
Journal:  N Engl J Med       Date:  2014-11-16       Impact factor: 91.245

2.  BRAF mutations are detectable in conjunctival but not uveal melanomas.

Authors:  Hayley E Spendlove; Bertil E Damato; Jane Humphreys; Karen T Barker; Paul S Hiscott; Richard S Houlston
Journal:  Melanoma Res       Date:  2004-12       Impact factor: 3.599

3.  Management of conjunctival malignant melanoma: a review and update.

Authors:  James R Wong; Afshan A Nanji; Anat Galor; Carol L Karp
Journal:  Expert Rev Ophthalmol       Date:  2014-06

4.  Known and novel ocular toxicities of biologics, targeted agents, and traditional chemotherapeutics.

Authors:  Anne L Kunkler; Elaine M Binkley; Dimosthenis Mantopoulos; Andrew J Hendershot; Matthew P Ohr; Kari L Kendra; Frederick H Davidorf; Colleen M Cebulla
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2019-05-16       Impact factor: 3.117

5.  Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis.

Authors:  Sandra P D'Angelo; James Larkin; Jeffrey A Sosman; Celeste Lebbé; Benjamin Brady; Bart Neyns; Henrik Schmidt; Jessica C Hassel; F Stephen Hodi; Paul Lorigan; Kerry J Savage; Wilson H Miller; Peter Mohr; Ivan Marquez-Rodas; Julie Charles; Martin Kaatz; Mario Sznol; Jeffrey S Weber; Alexander N Shoushtari; Mary Ruisi; Joel Jiang; Jedd D Wolchok
Journal:  J Clin Oncol       Date:  2016-11-07       Impact factor: 44.544

Review 6.  Ipilimumab-induced Ocular and Orbital Inflammation--A Case Series and Review of the Literature.

Authors:  Evangelia Papavasileiou; Sashank Prasad; Suzanne K Freitag; Lucia Sobrin; Ann-Marie Lobo
Journal:  Ocul Immunol Inflamm       Date:  2015-03-11       Impact factor: 3.070

7.  Clinical predictive factors for development of recurrence and metastasis in conjunctival melanoma: a review of 68 cases.

Authors:  P De Potter; C L Shields; J A Shields; H Menduke
Journal:  Br J Ophthalmol       Date:  1993-10       Impact factor: 4.638

8.  Margins of excision and prognostic factors for cutaneous eyelid melanomas.

Authors:  Varun Harish; Jeremy S Bond; Richard A Scolyer; Lauren E Haydu; Robyn P M Saw; Michael J Quinn; Ross S Benger; Roger F Uren; Jonathan R Stretch; Kerwin F Shannon; John F Thompson
Journal:  J Plast Reconstr Aesthet Surg       Date:  2013-05-17       Impact factor: 2.740

9.  Anti-PD-1/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B/C infection.

Authors:  Martin Tio; Rajat Rai; Ogochukwu M Ezeoke; Jennifer L McQuade; Lisa Zimmer; Chloe Khoo; John J Park; Lavinia Spain; Samra Turajlic; Luke Ardolino; Desmond Yip; Simone M Goldinger; Justine V Cohen; Michael Millward; Victoria Atkinson; Alisa Y Kane; Paolo A Ascierto; Claus Garbe; Ralf Gutzmer; Douglas B Johnson; Hira A Rizvi; Anthony M Joshua; Matthew D Hellmann; Georgina V Long; Alexander M Menzies
Journal:  Eur J Cancer       Date:  2018-10-20       Impact factor: 9.162

10.  PD-1 and CTLA4: Two checkpoints, one pathway?

Authors:  Lucy S K Walker
Journal:  Sci Immunol       Date:  2017-05-12
View more
  1 in total

Review 1.  Update on Immune Checkpoint Inhibitors for Conjunctival Melanoma.

Authors:  Ho-Seok Sa; Claire Daniel; Bita Esmaeli
Journal:  J Ophthalmic Vis Res       Date:  2022-08-15
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.